Cadrenal Therapeutics Inc (CVKD) News

Form 424B5 - Prospectus [Rule 424(b)(5)]

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Lays out Phase 3 Clinical and Regulatory Path for Tecarfarin and Three-Year Strategic Plan Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), announced...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook PR...

Form S-3 - Registration statement under Securities Act of 1933

Form D - Notice of Exempt Offering of Securities

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE PR Newswire PONTE VEDRA, Fla., Nov. 7, 2024...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds PR Newswire PONTE VEDRA...